Shares of Sequenom have risen sharply for the fourth week in a row, climbing 11.5 percent for the five-day trading period ended Tuesday to lead all stocks in the BCW Index. Sequenom’s shares have doubled over the past month as the firm in-licensed rights to a next-generation sequencing technology and launched a new assay design and validation service.
Cepheid, whose shares have risen throughout the year, led decliners in the Index this week with a drop of 10.1 percent as investors took profits. Its shares had a strong Tuesday, though, gaining 4.2 percent after the firm was mentioned during a CNBC report on hospital Staph infections.
Overall, the Index dropped .7 percent for the tracking period. In comparison, the Dow Jones Industrial Average fell 1.8 percent, the Nasdaq dropped 1.4 percent, and the Nasdaq Biotech Index bucked the trend by closing up .2 percent for the week.